Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19,The Journal of Clinical Investigation

当前位置： X-MOL 学术 › J. Clin. Invest. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19
The Journal of Clinical Investigation ( IF 15.9 ) Pub Date : 2021 , DOI: 10.1172/jci152264
Sixten Körper ₁ , Manfred Weiss ₂ , Daniel Zickler ₃ , Thomas Wiesmann ₄ , Kai Zacharowski ₅ , Victor M Corman ₆ , Beate Grüner ₇ , Lucas Ernst ₃ , Peter Spieth ₈ , Philipp M Lepper ₉ , Martin Bentz ₁₀ , Sebastian Zinn ₅ , Gregor Paul ₁₁ , Johannes Kalbhenn ₁₂ , Matthias M Dollinger ₁₃ , Peter Rosenberger ₁₄ , Thomas Kirschning ₁₅ , Thomas Thiele ₁₆ , Thomas Appl ₁ , Benjamin Mayer ₁₇ , Michael Schmidt ₁₈ , Christian Drosten ₆ , Hinnerk Wulf ₄ , Jan Matthias Kruse ₃ , Bettina Jungwirth ₂ , Erhard Seifried ₁₈ , Hubert Schrezenmeier ₁ ,

Affiliation

Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, and Institute of Transfusion Medicine, and.
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Ulm, Ulm University, Ulm, Germany.
Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, corporate member of Free University Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Department of Anaesthesiology and Intensive Care Medicine, Philipps University Marburg, Marburg, Germany.
Clinic of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Frankfurt, Germany.
Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Free University Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health and German Centre for Infection Research, Berlin, Germany.
Division of Infectious Diseases, University Hospital and Medical Center Ulm, Ulm, Germany.
Department of Anesthesiology and Critical Care Medicine, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany.
Department of Internal Medicine V - Pneumology, Allergology, Intensive Care Medicine, Saarland University Hospital, Homburg, Germany.
Department of Internal Medicine III, Hospital of Karlsruhe, Karlsruhe, Germany.
Department of Gastroenterology, Hepatology, Pneumology and Infectious Diseases, Klinikum Stuttgart, Stuttgart, Germany.
Department of Anesthesiology and Critical Care, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Medical Clinic I, Klinikum Landshut, Landshut, Germany.
Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany.
Department of Anaesthesiology and Surgical Intensive Care Medicine, University of Heidelberg, University Medical Centre Mannheim, Mannheim, Germany.
Institute of Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald, Germany.
Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, Frankfurt, Germany.

BACKGROUND. COVID-19 convalescent plasma (CCP) has been considered a treatment option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring respiratory support or intensive care treatment.

中文翻译：

用于重症 COVID-19 患者的高剂量恢复期血浆的 CAPSID 随机试验结果

背景。COVID-19 恢复期血浆 (CCP) 已被认为是 COVID-19 的一种治疗选择。该试验评估了含有高剂量 CCP 的中和抗体对需要呼吸支持或重症监护治疗的 COVID-19 住院成人的疗效。

更新日期：2021-10-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>